Vaccine Adjuvant Market

Vaccine Adjuvant Market Size (2022 to 2027)

As per our research report, the size of the global vaccine adjuvant market is forecasted to grow USD 1072.1 million by 2027, which was worth USD 642 million in 2022. The market is estimated to showcase a CAGR of 10.8% during the forecast period.

The global vaccine adjuvants market comprises veterinary and human adjuvants, which are used to increase the efficiency of vaccines. Vaccine adjuvants are accredited with assisting to boost the immune response in the host post-vaccination. Immunologists and infectious disease specialists are in covenant over the advantageous uses of adjuvants in vaccines today. Notably, as a means to decrease the number of doses, surge the probability of a continuous immunological response and reduce the overall prevalence of the disease.

The immune response to vaccine antigens has been improved with the use of adjuvants for decades. They recover the body's immune reaction and frequently allow for lesser amounts of a deactivated virus or bacteria to be used in a vaccine. However, more than one adjuvant may be present in the final vaccine product.

MARKET DRIVERS 

Increasing incidence of infectious and zoonotic diseases, growing focus on vaccination programs by numerous government bodies, and rising focus on enhanced and long-term immunization besides current and emerging diseases are primarily accelerating the global vaccine adjuvant market.

Additionally, growing R&D expenditure and attainments, associations, and agreements by companies is another major factor driving the growth of this market. Advancements in adjuvant formulations, the growing adoption rate of recombinant subunit, and synthetic vaccines provide an additional boost to the global vaccine adjuvant market. Growth opportunities that are likely to boost the global vaccine adjuvant market are growing demand for vaccine adjuvants, untouched market areas in developing countries are offering sizable shares for adjuvant vaccine manufacturers and key players in the market.

MARKET RESTRAINTS:

Side effects associated with the adjuvants and high toxicity adjuvants are the primary restraint to the global vaccine adjuvant market. High costs associated with adjuvant-based research and established protection is majorly restraining the market growth. The denying effect of adjuvants' toxicity on the vaccine's manufacturing cost and protective profiles inhibit the growing market demand. The adverse effects of adjuvants and high-toxicity adjuvant are factors impeding the vaccine adjuvant market growth during the forecasting timeline. Moreover, insufficient knowledge among people and inadequate healthcare facilities hampers the growing market rate. Low research activities in its development also hinder the market.

Impact of COVID-19 on the global vaccine adjuvant market:

During the pandemic crisis, import and export activities have been restricted because of lockdown. The COVID-19 pandemic crisis is projected to impact market growth positively, majorly. According to a research article in Nature Reviews Immunology 2020, aluminum-based vaccine adjuvants offer a glide path to influence high levels of neutralizing antibodies identified as a basis of the safety allocated by the COVID-19 vaccines. For instance, in May 2020, GSK considered generating 1 billion doses of its pandemic vaccine adjuvant system in 2021 to develop multiple adjuvanted COVID-19, vaccine candidates. India's government (GOI) has permitted INR 100 crores from PM-CARES funds to establish the COVID-19 vaccine. Presently, there are nearly 25 vaccine development work is continuous, in association with industry-academia collaboration. Moreover, in China, in April 2020, announced the surplus funding of USD 30 million to the World Health Organization (WHO) for handling the COVID-19 pandemic. 

REPORT COVERAGE:

This market research report on the global vaccine adjuvant market has been segmented based on the type, route of administration, mechanism of action, and region.

Vaccine Adjuvant Market – By Type:

• Aluminum Salts
• Tensoactive Adjuvants
• Adjuvant Emulsions
• Bacteria Derived Adjuvants
• Liposome Adjuvants
• Carbohydrate Adjuvants

Based on type, the carbohydrate adjuvants segment contributes a significant share and is anticipated to grow further during the forecast period.

The aluminum salts type segment is estimated to grow at a healthy CAGR during the forecast period due to rising innovation and the introduction of particulate adjuvants in the market. Aluminum salts vaccine has a presence and growing continuously in the market for the last two decades due to the safety of cancer patients. Also, new adjuvants have come up with an innovative facility such as more muscular battle to disease and having a more shelf life than others due to easier availability of aluminum salts in the nature and high adoption of particulate vaccines.

Vaccine Adjuvant Market – By Route of administration:

• Oral
• Intradermal
• Subcutaneous
• Intranasal
• Intramuscular

Based on the administration route, the Intramuscular segment is dominating the vaccine adjuvants market regarding the route of administration as this is the fastest and highly effective route. The intradermal route segment is likely to contribute a significant share to the market as it takes more time for absorption and action. 

Vaccine Adjuvant Market – By Mechanism of Action:

• Immune Stimulants
• Carriers
• Vehicle Adjuvants

Based on the mechanism of action, the Immune Stimulants segment dominates the market due to the high demand for adjuvants for stimulating antigens to the immune system.

Vaccine Adjuvant Market – By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa

North America, followed by Europe, lead the vaccine adjuvants market. Growth in the North American segment is mainly driven by the fast-increasing elderly population and rising government funding in North American countries. The North American market is also overgrowing due to innovations and increasing product portfolios of the key players, a rise in investments of R & D.

The European market is dominating due to an increase in patients affected by diseases like cancer and other infections. The Asia Pacific and Africa are displaying consistent growth and expected to maintain the trend due to the increasing population and diseases like HIV, hepatitis, cancer, influenza, and others.

KEY MARKET PARTICIPANTS:

Some of the promising companies operating in the global vaccine adjuvants market include MPV Technologies (U.S.), Avanti Polar Lipids, Novavax Inc. (U.S.), Brenntag Biosector (Denmark), SEPPIC (France), Agenus, Inc. (U.S.), Invivogen (U.S.), SPI Pharma, Inc. (U.S.), CSL Limited (Australia), and OZ Biosciences (France).

RECENT MARKET DEVELOPMENTS:

• In 2020, The U.S. food and drug administration approved Seqirus for its new product AUNDEZ to treat Influenza prevention. It is the first monovalent vaccine adjuvant to protect against influenza A H5N1 in the pandemic situation.
• In 2020, GSK announced it comes into the market with innovative doses of vaccine adjuvant to enhance the COVID-19 outbreak. GSK has invested a high amount in developing 1 billion doses of adjuvanted vaccine next year.
• In 2018, Croda acquired the Brenntag bio sector to develop an adjuvant vaccine for serving humans and the veterinary market.